3 results
Search Results
2. OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19.
- Author
-
Beata Skarzynska, Magdalena, Krol, Bartlomiej, Czajka, Natalia, and Czajka, Lukasz
- Subjects
- *
ANTIVIRAL agents , *AUDIOMETRY , *CHLOROQUINE , *DIAGNOSIS , *HEARING disorders , *OTOACOUSTIC emissions , *AZITHROMYCIN , *OTOTOXICITY , *OSELTAMIVIR , *TOCILIZUMAB , *COVID-19 , *DISEASE risk factors , *SYMPTOMS - Abstract
Background: Actual level of knowledge of treatment of COVID-19 disease caused by a type of coronavirus is that the disease cannot at present be cured by targeted therapy. Worldwide research is aiming to find a specific treatment, such as a vaccine or drug, for this type of coronavirus; this may help improve the situation, but it is highly expensive and time-consuming. The purpose of this paper is to review drug therapies approved in different parts of the world to treat COVID-19 and draw attention to ototoxicity as one of the adverse side-effects. Material and methods: Review of current literature was done in the scientific databases PubMed, ResearchGate, GoogleScholar, and Science-Direct. Studies were reviewed with reference to the inclusion criteria, then graded to assess the internal and external validity, leaving 50 studies for review. Results: According to scientific reports, possible antiviral pharmacological agents to treat COVID-19 consist of chloroquine, hydroxychloroquine, azitromycine, oseltamivir, and tocilizumab. In some cases, certain combinations may lead to additive ototoxicity as an adverse effect. Ototoxicity may be manifested by sensory and nervous hearing loss, tinnitus, imbalance, and cochlear-mandibular symptoms, which are sometimes temporary but sometimes permanent. Conclusion: Drug ototoxicity is well known as a cause of cochlear hearing loss, and so the use of new pharmacotherapy methods and drug combinations in the fight against the new coronavirus may have harmful effects. Ototoxicity needs to be taken into account. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro.
- Author
-
Song, Yabin, Deng, Yongqiang, Wang, Huiqiang, Bei, Zhuchun, Gu, Hongjing, Zhao, Hui, Wang, Hong, Zhang, Dongna, Xu, Likun, Wang, Baogang, Li, Yuhuan, and Wang, Hongquan
- Subjects
- *
COVID-19 , *ANTIVIRAL agents , *ANTIMALARIALS , *COVID-19 pandemic , *DRUG efficacy , *DRUGS , *SARS-CoV-2 , *CHLOROQUINE - Abstract
COVID-19 has spread around the world and caused serious public health and social problems. Although several vaccines have been authorized for emergency use, new effective antiviral drugs are still needed. Some repurposed drugs including Chloroquine, Hydroxychloroquine and Remdesivir were immediately used to treat COVID-19 after the pandemic. However, the therapeutic effects of these drugs have not been fully demonstrated in clinical studies. In this paper, we found an antimalarial drug, Naphthoquine, showed good broad-spectrum anti-coronavirus activity. Naphthoquineinhibited HCoV-229E, HCoV-OC43 and SARS-CoV-2 replication in vitro, with IC50 = 2.05 ± 1.44 μM, 5.83 ± 0.74 μM, and 2.01 ± 0.38 µM, respectively. Time-of-addition assay was also performed to explore at which stage Naphthoquine functions during SARS-CoV-2 replication. The results suggested that Naphthoquine may influence virus entry and post-entry replication. Considering the safety of Naphthoquine was even better than that of Chloroquine, we think Naphthoquine has the potential to be used as a broad-spectrum drug for coronavirus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.